Aarti Drugs Ltd Analyst Rating
based on 1 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 1 analysts offering long term price targets for Aarti Drugs Ltd. An average target of ₹536
Source: S&P Global Market Intelligence
Aarti Drugs Ltd Share analysis
Aarti Drugs Ltd price forecast by 1 analysts
Upside of7.23%
High
₹536
Target
₹536.00
Low
₹536
Aarti Drugs Ltd target price ₹536, a slight upside of 7.23% compared to current price of ₹495. According to 1 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aarti Drugs Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.84%
Forecast
Actual
Including amortisation and stock based compensations
Aarti Drugs Ltd EPS growth forecast
EPS estimate Q1, FY2026:108.58%
Forecast
Actual
Source: S&P Global Market Intelligence
Aarti Drugs Ltd Performance
Day's Low
Day's High
₹493.05₹501.8552 Week's Low
52 Week's High
₹431.05₹635
| Returns % | |
| 1 Month Return | -6.1 % |
| 3 Month Return | -4.17 % |
| 1 Year Return | + 3.22 % |
| Market Stats | |
| Previous Close | ₹499.85 |
| Open | ₹501.85 |
| Volume | 1.12L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,595.37Cr |
Aarti Drugs Ltd Key Statistics
| P/E Ratio | 29.32 |
| PEG Ratio | -12.53 |
| Market Cap | ₹4,595.37 Cr |
| P/B Ratio | 3.39 |
| EPS | 18.66 |
| Dividend Yield | 0.23 |
| Sector | Pharmaceuticals |
| ROE | 12.39 |
Aarti Drugs Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,595.37 Cr | 64.91% | 0.64 | ₹171 Cr | ₹2,528 Cr | |
| HOLD | ₹31,560.96 Cr | 127.13% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹18,791.82 Cr | 30.25% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,996.36 Cr | 12.52% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹14,535.09 Cr | 43.59% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Aarti Drugs Ltd Mutual Fund Holdings
About Aarti Drugs Ltd
Share Price: ₹495.00 per share as on 21 Oct, 2024 04:01 PM
Market Capitalisation: ₹4,595.37Cr as of today
Revenue: ₹555.34Cr as on June 2024 (Q2 24)
Net Profit: ₹33.27Cr as on June 2024 (Q2 24)
Listing date: 03 Oct, 1996
Chairperson Name: Prakash M Patil
| Organisation | Aarti Drugs Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Aarti Drugs Ltd
Aarti Drugs Gains GMP Certification, Shares Rise - 04 Oct, 2024
Aarti Drugs' subsidiary, Pinnacle Life Science, received a GMP compliance certificate from UK MHRA, enabling UK exports. Shares rose 3% following the announcement.
Aarti Drugs Faces USFDA Observations - 25 Sep, 2024
Aarti Drugs received seven observations from the USFDA following an inspection of its Tarapur manufacturing plant. The company stated that none of the observations pertain to data integrity and will work closely with the USFDA to address the issues. Shares fell by 1.83% to Rs 520.30.
Aarti Drugs Faces USFDA Scrutiny with Observations - 23 Sep, 2024
Aarti Drugs' API manufacturing facility in Tarapur received seven observations from the USFDA following an inspection. None of the issues pertained to data integrity, but shares fell marginally post-announcement.
Aarti Drugs Faces USFDA Observations at Maharashtra Facility - 21 Sep, 2024
Aarti Drugs reported that its Maharashtra API manufacturing facility received seven observations from the USFDA following an inspection. The company plans to address these points and noted that none were related to data integrity.
Insights on Aarti Drugs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 5.70% to 6.25% in Sep 2024 quarter
NO EFFECTRetail Holding Unchanged
Retail Investor holdings remained unchanged at 34.02% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 133.4% return, outperforming this stock by 152.2%
- NO EFFECT
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 83.8% return, outperforming this stock by 80.5%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 2.96% to 2.50% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, AARTIDRUGS stock has moved down by -18.8%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 621.07 Cr → 556.45 Cr (in ₹), with an average decrease of 10.4% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 47.37 Cr → 33.24 Cr (in ₹), with an average decrease of 29.8% per quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 55.67% to 55.64% in Sep 2024 quarter
Aarti Drugs Ltd Financials
Index Inclusions
Aarti Drugs Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 55.64% | ||
| Foreign Institutions | 2.5% | ||
| Mutual Funds | 6.25% | 9.64 | |
| Retail Investors | 34.02% | 0.00 | |
| Others | 1.58% |
Aarti Drugs Ltd Key Indicators
Aarti Drugs Ltd Valuation
Aarti Drugs Ltd in the last 5 years
Lowest (8.29x)
March 31, 2020
Today (29.32x)
October 18, 2024
Industry (58.10x)
October 18, 2024
Highest (57.24x)
August 24, 2020
Aarti Drugs Ltd Earnings and Dividends
Aarti Drugs Ltd Earnings Results
Aarti Drugs Ltd’s net profit fell -30.53% since last year same period to ₹33.24Cr in the Q1 2024-2025. On a quarterly growth basis, Aarti Drugs Ltd has generated -29.83% fall in its net profits since last 3-months.
Read More about Earnings ResultsAarti Drugs Ltd Dividends January,2024
In the quarter ending December 2023, Aarti Drugs Ltd has declared dividend of ₹1 - translating a dividend yield of 0.40%.
Read More about Dividends
Aarti Drugs Ltd Technicals Summary
Bearish
Neutral
Bullish
Aarti Drugs Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Aarti Drugs Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Aarti Drugs Ltd shares.
Aarti Drugs Ltd (AARTIDRUGS) share price today is ₹495
Aarti Drugs Ltd is listed on NSE
Aarti Drugs Ltd is listed on BSE
- Today’s highest price of Aarti Drugs Ltd is ₹501.85.
- Today’s lowest price of Aarti Drugs Ltd is ₹493.05.
PE Ratio of Aarti Drugs Ltd is 29.32
PE ratio = Aarti Drugs Ltd Market price per share / Aarti Drugs Ltd Earnings per share
Today’s traded volume of Aarti Drugs Ltd(AARTIDRUGS) is 1.12L.
Today’s market capitalisation of Aarti Drugs Ltd(AARTIDRUGS) is ₹4595.37Cr.
| Aarti Drugs Ltd(AARTIDRUGS | Price |
|---|---|
52 Week High | ₹635 |
52 Week Low | ₹431.05 |
Aarti Drugs Ltd(AARTIDRUGS) share price is ₹495. It is down -22.05% from its 52 Week High price of ₹635
Aarti Drugs Ltd(AARTIDRUGS) share price is ₹495. It is up 14.84% from its 52 Week Low price of ₹431.05
| Aarti Drugs Ltd(AARTIDRUGS | Returns |
|---|---|
1 Day Returns | -4.85% |
1 Month Returns | -6.1% |
3 Month Returns | -4.17% |
1 Year Returns | 3.22% |